Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

Determinants of low bone mineral density in people with multiple sclerosis: Role of physical activity.

Cleland BT, Papanek P, Ingraham BA, Harkins A, Garnier-Villarreal M, Woo D, Csuka ME, V Ng A.

Mult Scler Relat Disord. 2019 Nov 23;38:101864. doi: 10.1016/j.msard.2019.101864. [Epub ahead of print]

PMID:
31801106
2.

Efficacy of Osteoporosis Prevention Smartphone App.

Ryan P, Brown RL, Csuka ME, Papanek P.

Nurs Res. 2019 Sep 13. doi: 10.1097/NNR.0000000000000392. [Epub ahead of print]

PMID:
31568199
3.

Risk Factors for Mortality and Cardiopulmonary Hospitalization in Systemic Sclerosis Patients At Risk for Pulmonary Hypertension, in the PHAROS Registry.

Hsu VM, Chung L, Hummers LK, Shah A, Simms R, Bolster M, Hant FN, Silver RM, Fischer A, Hinchcliff ME, Varga J, Goldberg AZ, Derk CT, Schiopu E, Khanna D, Shapiro LS, Domsic RT, Medsger T, Mayes MD, Furst D, Csuka ME, Molitor JA, Saketkoo LA, Salazar CR, Steen VD.

J Rheumatol. 2019 Feb;46(2):176-183. doi: 10.3899/jrheum.180018. Epub 2018 Oct 1.

PMID:
30275260
4.

Background and method of the Striving to be Strong study a RCT testing the efficacy of a m-health self-management intervention.

Ryan P, Papanek P, Csuka ME, Brown ME, Hopkins S, Lynch S, Scheer V, Schlidt A, Yan K, Simpson P, Hoffman R; Striving to be Strong Team.

Contemp Clin Trials. 2018 Aug;71:80-87. doi: 10.1016/j.cct.2018.06.006. Epub 2018 Jun 9.

PMID:
29894865
5.

Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma.

Sullivan KM, Goldmuntz EA, Keyes-Elstein L, McSweeney PA, Pinckney A, Welch B, Mayes MD, Nash RA, Crofford LJ, Eggleston B, Castina S, Griffith LM, Goldstein JS, Wallace D, Craciunescu O, Khanna D, Folz RJ, Goldin J, St Clair EW, Seibold JR, Phillips K, Mineishi S, Simms RW, Ballen K, Wener MH, Georges GE, Heimfeld S, Hosing C, Forman S, Kafaja S, Silver RM, Griffing L, Storek J, LeClercq S, Brasington R, Csuka ME, Bredeson C, Keever-Taylor C, Domsic RT, Kahaleh MB, Medsger T, Furst DE; SCOT Study Investigators.

N Engl J Med. 2018 Jan 4;378(1):35-47.

6.

Utility of B-type natriuretic peptides in the assessment of patients with systemic sclerosis-associated pulmonary hypertension in the PHAROS registry.

Chung L, Fairchild RM, Furst DE, Li S, Alkassab F, Bolster MB, Csuka ME, Derk CT, Domsic RT, Fischer A, Frech TM, Gomberg-Maitland M, Gordon JK, Hinchcliff M, Hsu V, Hummers LK, Khanna D, Medsger TAJ, Molitor JA, Preston IR, Schiopu E, Shapiro L, Hant F, Silver R, Simms R, Varga J, Steen VD, Zamanian RT.

Clin Exp Rheumatol. 2017 Sep-Oct;35 Suppl 106(4):106-113. Epub 2016 Nov 10.

PMID:
27908301
7.

The Recurrence of Digital Ulcers in Patients with Systemic Sclerosis after Discontinuation of Oral Treprostinil.

Shah AA, Schiopu E, Chatterjee S, Csuka ME, Frech T, Goldberg A, Spiera R, Peng SL, McBride RJ, Cleveland JM, Steen V.

J Rheumatol. 2016 Sep;43(9):1665-71. doi: 10.3899/jrheum.151437. Epub 2016 Jun 15.

PMID:
27307535
8.

Pulmonary hypertension and interstitial lung disease within PHAROS: impact of extent of fibrosis and pulmonary physiology on cardiac haemodynamic parameters.

Fischer A, Swigris JJ, Bolster MB, Chung L, Csuka ME, Domsic R, Frech T, Hinchcliff M, Hsu V, Hummers LK, Gomberg-Maitland M, Mathai SC, Simms R, Steen VD.

Clin Exp Rheumatol. 2014 Nov-Dec;32(6 Suppl 86):S-109-14. Epub 2014 Nov 4.

PMID:
25372796
9.

Development of pulmonary hypertension in a high-risk population with systemic sclerosis in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) cohort study.

Hsu VM, Chung L, Hummers LK, Wigley F, Simms R, Bolster M, Silver R, Fischer A, Hinchcliff ME, Varga J, Goldberg AZ, Derk CT, Schiopu E, Khanna D, Shapiro LS, Domsic RT, Medsger T, Mayes MD, Furst D, Csuka ME, Molitor JA, Alkassab F, Steen VD.

Semin Arthritis Rheum. 2014 Aug;44(1):55-62. doi: 10.1016/j.semarthrit.2014.03.002. Epub 2014 Mar 5.

PMID:
24709277
10.

2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative.

van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, Matucci-Cerinic M, Naden RP, Medsger TA Jr, Carreira PE, Riemekasten G, Clements PJ, Denton CP, Distler O, Allanore Y, Furst DE, Gabrielli A, Mayes MD, van Laar JM, Seibold JR, Czirjak L, Steen VD, Inanc M, Kowal-Bielecka O, Müller-Ladner U, Valentini G, Veale DJ, Vonk MC, Walker UA, Chung L, Collier DH, Csuka ME, Fessler BJ, Guiducci S, Herrick A, Hsu VM, Jimenez S, Kahaleh B, Merkel PA, Sierakowski S, Silver RM, Simms RW, Varga J, Pope JE.

Arthritis Rheum. 2013 Nov;65(11):2737-47. doi: 10.1002/art.38098. Epub 2013 Oct 3.

11.

Survival and predictors of mortality in systemic sclerosis-associated pulmonary arterial hypertension: outcomes from the pulmonary hypertension assessment and recognition of outcomes in scleroderma registry.

Chung L, Domsic RT, Lingala B, Alkassab F, Bolster M, Csuka ME, Derk C, Fischer A, Frech T, Furst DE, Gomberg-Maitland M, Hinchcliff M, Hsu V, Hummers LK, Khanna D, Medsger TA Jr, Molitor JA, Preston IR, Schiopu E, Shapiro L, Silver R, Simms R, Varga J, Gordon JK, Steen VD.

Arthritis Care Res (Hoboken). 2014 Mar;66(3):489-95. doi: 10.1002/acr.22121.

12.

Computer-based intervention to enhance self-management of calcium and vitamin D intake in women.

Ryan P, Maierle D, Csuka ME, Thomson A, Szabo A.

West J Nurs Res. 2013 Sep;35(8):986-1010. doi: 10.1177/0193945913483369. Epub 2013 Mar 27.

13.

Gastric antral vascular ectasia and its clinical correlates in patients with early diffuse systemic sclerosis in the SCOT trial.

Hung EW, Mayes MD, Sharif R, Assassi S, Machicao VI, Hosing C, St Clair EW, Furst DE, Khanna D, Forman S, Mineishi S, Phillips K, Seibold JR, Bredeson C, Csuka ME, Nash RA, Wener MH, Simms R, Ballen K, Leclercq S, Storek J, Goldmuntz E, Welch B, Keyes-Elstein L, Castina S, Crofford LJ, Mcsweeney P, Sullivan KM.

J Rheumatol. 2013 Apr;40(4):455-60. doi: 10.3899/jrheum.121087. Epub 2013 Feb 15.

14.

Baseline characteristics and follow-up in patients with normal haemodynamics versus borderline mean pulmonary arterial pressure in systemic sclerosis: results from the PHAROS registry.

Bae S, Saggar R, Bolster MB, Chung L, Csuka ME, Derk C, Domsic R, Fischer A, Frech T, Goldberg A, Hinchcliff M, Hsu V, Hummers L, Schiopu E, Mayes MD, McLaughlin V, Molitor J, Naz N, Furst DE, Maranian P, Steen V, Khanna D.

Ann Rheum Dis. 2012 Aug;71(8):1335-42. doi: 10.1136/annrheumdis-2011-200546. Epub 2012 Feb 2.

15.

Items for developing revised classification criteria in systemic sclerosis: Results of a consensus exercise.

Fransen J, Johnson SR, van den Hoogen F, Baron M, Allanore Y, Carreira PE, Czirják L, Denton CP, Distler O, Furst DE, Gabrielli A, Herrick A, Inanc M, Kahaleh B, Kowal-Bielecka O, Medsger TA Jr, Mueller-Ladner U, Riemekasten G, Sierakowski S, Valentini G, Veale D, Vonk MC, Walker U, Chung L, Clements PJ, Collier DH, Csuka ME, Jimenez S, Merkel PA, Seibold JR, Silver R, Steen V, Tyndall A, Matucci-Cerinic M, Pope JE, Khanna D.

Arthritis Care Res (Hoboken). 2012 Mar;64(3):351-7. doi: 10.1002/acr.20679.

16.

Generalized morphea after breast cancer radiation therapy.

Kushi J, Csuka ME.

Case Rep Rheumatol. 2011;2011:951948. doi: 10.1155/2011/951948. Epub 2011 Nov 3.

17.

Abnormal fibrillin-1 expression and chronic oxidative stress mediate endothelial mesenchymal transition in a murine model of systemic sclerosis.

Xu H, Zaidi M, Struve J, Jones DW, Krolikowski JG, Nandedkar S, Lohr NL, Gadicherla A, Pagel PS, Csuka ME, Pritchard KA, Weihrauch D.

Am J Physiol Cell Physiol. 2011 Mar;300(3):C550-6. doi: 10.1152/ajpcell.00123.2010. Epub 2010 Dec 15.

18.

Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: a randomized, double-blind, placebo-controlled trial.

Khanna D, Clements PJ, Furst DE, Korn JH, Ellman M, Rothfield N, Wigley FM, Moreland LW, Silver R, Kim YH, Steen VD, Firestein GS, Kavanaugh AF, Weisman M, Mayes MD, Collier D, Csuka ME, Simms R, Merkel PA, Medsger TA Jr, Sanders ME, Maranian P, Seibold JR; Relaxin Investigators and the Scleroderma Clinical Trials Consortium.

Arthritis Rheum. 2009 Apr;60(4):1102-11. doi: 10.1002/art.24380.

19.

MQX-503, a novel formulation of nitroglycerin, improves the severity of Raynaud's phenomenon: a randomized, controlled trial.

Chung L, Shapiro L, Fiorentino D, Baron M, Shanahan J, Sule S, Hsu V, Rothfield N, Steen V, Martin RW, Smith E, Mayes M, Simms R, Pope J, Kahaleh B, Csuka ME, Gruber B, Collier D, Sweiss N, Gilbert A, Dechow FJ, Gregory J, Wigley FM.

Arthritis Rheum. 2009 Mar;60(3):870-7. doi: 10.1002/art.24351.

20.

Effects of D-4F on vasodilation, oxidative stress, angiostatin, myocardial inflammation, and angiogenic potential in tight-skin mice.

Weihrauch D, Xu H, Shi Y, Wang J, Brien J, Jones DW, Kaul S, Komorowski RA, Csuka ME, Oldham KT, Pritchard KA.

Am J Physiol Heart Circ Physiol. 2007 Sep;293(3):H1432-41. Epub 2007 May 11.

21.

Outcome measurements in scleroderma: results from a delphi exercise.

Gazi H, Pope JE, Clements P, Medsger TA, Martin RW, Merkel PA, Kahaleh B, Wollheim FA, Baron M, Csuka ME, Emery P, Belch JF, Hayat S, Lally EV, Korn JH, Czirjak L, Herrick A, Voskuyl AE, Bruehlmann P, Inanc M, Furst DE, Black C, Ellman MH, Moreland LW, Rothfield NF, Hsu V, Mayes M, McKown KM, Krieg T, Siebold JR.

J Rheumatol. 2007 Mar;34(3):501-9. Epub 2007 Feb 1.

PMID:
17299843
22.

Severe gastrointestinal involvement in systemic sclerosis: report of five cases and review of the literature.

Jaovisidha K, Csuka ME, Almagro UA, Soergel KH.

Semin Arthritis Rheum. 2005 Feb;34(4):689-702. Review.

PMID:
15692963
23.

Minocycline is not effective in systemic sclerosis: results of an open-label multicenter trial.

Mayes MD, O'Donnell D, Rothfield NF, Csuka ME.

Arthritis Rheum. 2004 Feb;50(2):553-7.

24.

Leflunomide treatment of Crohn's disease patients intolerant to standard immunomodulator therapy.

Prajapati DN, Knox JF, Emmons J, Saeian K, Csuka ME, Binion DG.

J Clin Gastroenterol. 2003 Aug;37(2):125-8.

PMID:
12869881
25.

Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon.

Merkel PA, Herlyn K, Martin RW, Anderson JJ, Mayes MD, Bell P, Korn JH, Simms RW, Csuka ME, Medsger TA Jr, Rothfield NF, Ellman MH, Collier DH, Weinstein A, Furst DE, Jiménez SA, White B, Seibold JR, Wigley FM; Scleroderma Clinical Trials Consortium.

Arthritis Rheum. 2002 Sep;46(9):2410-20.

26.

Recombinant human relaxin in the treatment of scleroderma. A randomized, double-blind, placebo-controlled trial.

Seibold JR, Korn JH, Simms R, Clements PJ, Moreland LW, Mayes MD, Furst DE, Rothfield N, Steen V, Weisman M, Collier D, Wigley FM, Merkel PA, Csuka ME, Hsu V, Rocco S, Erikson M, Hannigan J, Harkonen WS, Sanders ME.

Ann Intern Med. 2000 Jun 6;132(11):871-9.

PMID:
10836913
27.

Polysynovitis associated with acute Epstein-Barr virus infection.

McCarty DJ, Csuka ME.

J Rheumatol. 1998 Oct;25(10):2039-40. Review. No abstract available.

PMID:
9779871
28.

Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study.

Wigley FM, Korn JH, Csuka ME, Medsger TA Jr, Rothfield NF, Ellman M, Martin R, Collier DH, Weinstein A, Furst DE, Jimenez SA, Mayes MD, Merkel PA, Gruber B, Kaufman L, Varga J, Bell P, Kern J, Marrott P, White B, Simms RW, Phillips AC, Seibold JR.

Arthritis Rheum. 1998 Apr;41(4):670-7.

PMID:
9550476
29.

Concurrent gout and Mycobacterium tuberculosis arthritis.

Lorenzo JP, Csuka ME, Derfus BA, Gotoff RA, McCarthy GM.

J Rheumatol. 1997 Jan;24(1):184-6.

PMID:
9002033
30.
31.

The prevalence of sexual abuse in women with fibromyalgia.

Taylor ML, Trotter DR, Csuka ME.

Arthritis Rheum. 1995 Feb;38(2):229-34.

PMID:
7848313
32.

Activity of oxidative routes of metabolism of debrisoquin, mephenytoin, and dapsone is unrelated to the pathogenesis of vinyl chloride-induced disease.

Black C, May G, Csuka ME, Lupoli S, Wilkinson GR, Branch RA.

Clin Pharmacol Ther. 1992 Dec;52(6):659-67.

PMID:
1458774
33.

Bone remodelling after growth factor and cyclosporine A therapy for aplastic anemia.

Derfus BA, Csuka ME, Carrera GF, Hanson GA, Smith RE.

J Rheumatol. 1991 May;18(5):738-42.

PMID:
1865422
34.

Scleroderma is associated with differences in individual routes of drug metabolism: a study with dapsone, debrisoquin, and mephenytoin.

May DG, Black CM, Olsen NJ, Csuka ME, Tanner SB, Bellino L, Porter JA, Wilkinson GR, Branch RA.

Clin Pharmacol Ther. 1990 Sep;48(3):286-95.

PMID:
2401127
35.

Aspirin and the treatment of rheumatoid arthritis.

Csuka ME, McCarty DJ.

Rheum Dis Clin North Am. 1989 Aug;15(3):439-54. Review.

PMID:
2672131
36.

Aspirin in the treatment of chronic inflammatory arthritis.

McCarty D, Csuka ME.

JAMA. 1987 Mar 13;257(10):1331. No abstract available.

PMID:
3820440
37.

Gold induced aplastic anemia. Complete response to corticosteroids, plasmapheresis, and N-acetylcysteine infusion.

Hansen RM, Csuka ME, McCarty DJ, Saryan LA.

J Rheumatol. 1985 Aug;12(4):794-7.

PMID:
4057204
38.

Transient hypothermia after corticosteroid treatment of subacute cutaneous lupus erythematosus.

Csuka ME, McCarty DJ.

J Rheumatol. 1984 Feb;11(1):112-3. No abstract available.

PMID:
6699827
39.

Interpretation of laboratory results in the elderly. 1. A clinician's guide to hematologic and hepatorenal function tests.

Gambert SR, Csuka ME, Duthie EH Jr, Tiegs R.

Postgrad Med. 1982 Sep;72(3):147-52.

PMID:
7122336
40.

Erythromycin ethylsuccinate hepatotoxicity.

Sullivan D, Csuka ME, Blanchard B.

JAMA. 1980 Mar 14;243(10):1074. No abstract available.

PMID:
6965509

Supplemental Content

Loading ...
Support Center